Skip to main content

Akero Therapeutics Inc. (NASDAQ: AKRO) Sets New 52-Week High in Tuesday Morning Session

Shares of Akero Therapeutics Inc. (NASDAQ: AKRO) traded at a new 52-week high today and are currently trading at $26.11. So far today, approximately 33.17M shares have been exchanged, as compared to an average 30-day volume of 421.97k shares.

Akero Therapeutics Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.

Mentions of Akero Therapeutics Inc. on Twitter in the past 24 hours have totaled 1,099, as compared to 140 in the prior 24 hours (a change of 685%). On Stocktwits, posts totaled 758 for the same period, as compared to 6 in the prior 24 hours (a change of 12,533%).

Akero Therapeutics Inc. share prices have moved between a 52-week high of $29.73 and a 52-week low of $7.52. The stock has moved 3.11% over the past week.

To learn more about Akero therapeutics, inc., visit the company’s website at

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.